Every S-3 that Akari Therapeutics Plc (AKTX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A S-3 covers the shelf registration that lets an established company sell over time, so if you follow AKTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AKTX filings page.
Akari Therapeutics, Plc filed an amended shelf registration to permit the resale by existing holders of up to 5,999,999 American Depositary Shares (ADSs), representing 479,999,920,000 ordinary shares. These ADSs arise from a May 2026 private placement of ADSs, pre-funded warrants and Series H, I and J warrants, plus ADSs issued to the placement agent. The company is not selling any ADSs in this offering and will receive no proceeds from shareholder resales; all sale proceeds go to the selling shareholders. Akari may receive up to approximately $16.5 million only if all related warrants are exercised for cash, which it plans to use for research and development, general and administrative expenses and working capital. As of June 30, 2026, 140,032,769,533 ordinary shares were outstanding, a baseline figure, not the amount being registered. The filing highlights significant potential resale supply and detailed selling shareholder positions subject to 4.99% and 9.99% beneficial ownership limitations on warrant exercises.
Akari Therapeutics, Plc amends its registration statement (File No. 333-297257) solely to file certain exhibits. The amendment attaches amended Articles of Association, deposit agreement documents for American Depositary Shares, forms of warrants (including Pre-Funded, Series H, I, and J), the Securities Purchase Agreement dated May 20, 2026 and its June 23, 2026 amendment, and related legal opinions and consents. The filing is signed by Abizer Gaslightwala as President and CEO on July 8, 2026.
Akari Therapeutics, Plc is registering for resale 5,999,999 ADSs, representing 479,999,920,000 ordinary shares, for sale by the selling shareholders. This registration covers ADSs issued in a May 2026 private placement and ADSs issuable on exercise of several warrant series and pre-funded warrants. Each ADS represents 80,000 ordinary shares. The resale is by selling shareholders; Akari will not receive proceeds from those resales, although the company may receive proceeds if the registered warrants are exercised for cash.
The prospectus lists the selling shareholders, discloses a 4.99% or 9.99% beneficial ownership limitation on warrant exercises, and states the company had 140,032,769,533 ordinary shares outstanding as of June 30, 2026. The ADSs are listed on Nasdaq under the symbol AKTX and the prospectus includes customary risk factors about development-stage oncology operations, material weaknesses in internal control, and capital needs.